Cannabinoids have been the subject of many studies over the past fifty years. While THC has previously taken the spotlight, medical professionals are beginning to realize the importance of cannabidiol(CBD), another cannabinoid present in hemp that is not psychoactive. As a matter of fact, it may even surpass THC as the cannabinoid with the most potential. There have already been multiple clinical studies that point to this possibility. Here are three of them.

CBD For Anti-Psychosis.

The findings of a clinical trial regarding the use of cannabidiol as an antipsychotic were published in the Transl Psychiatry journal. This was a randomized, double-blind clinical study that compared the effectiveness of cannabidiol versus a leading antipsychotic drug when treating patients who suffered from schizophrenia. The findings of the study were surprising and have encouraged further research into the field.

Treating schizophrenia is an extremely difficult task. Even experienced professionals with the help of cutting edge medications cannot completely reverse the condition. What is known about the condition is that it many different neurotransmitters in the brain. In particular, it involves endocannabinoids, which are key components of the endocannabinoid system(ECS). Cannabidiol is a plant-based cannabinoid that directly mimics one of the cannabinoids in the human body.

This particular study tested the effectiveness of that cannabinoid while comparing it to one of the most effective antipsychotic drugs on the market. What did the study reveal? Cannabidiol was just as effective as the leading drug at combating the symptoms of schizophrenia, but the side effects were far better. Therefore, with more research, it could be possible to create an even more effective antipsychotic drug with little-to-none of the side effects that patients commonly suffer from today.

CBD for Arthritis.

Another study published in 2000 focused on the usefulness of CBD for treating collagen-induced arthritis(CIA). Unlike the previously mentioned study, this study did not involve humans. Instead, the test was performed with mice. The mice were given CIA and the CBD was provided after the onset of symptoms began. CIA is very similar to rheumatoid arthritis so the findings of this study could impact future treatments of that disease as well.

The study revealed that CBD could be used to slow or completely stop the progression of CIA in the mice. The effectiveness of the treatment was dependent on the actual dose. Interestingly, when increased to 20 mg/kg a day, the effect was minimal. At 5 mg/kg a day the disease was sufficiently repressed. Then, when dropping lower to 2.5 mg/kg per day, there was no effect.

This same study was conducted again in the future with similar mice. Once again, the same findings were revealed. The treatment was effective, but only within a certain zone. Both studies lasted for a period of 28 days with the best results appearing in mice who were given a dose of 5 mg/kg a day.

CBD For Epilepsy

Epilepsy is another area that has earned a lot of attention as of late. In particular, there are some forms that are considered treatment resistant. Patients with a treatment resistant form of epilepsy are at a high risk for suffering serious seizures and even death. In 2016, the findings of a study relating to the use of CBD in patients with treatment-resistant epilepsy was released.

CBD did not appear to be a “cure all” or “magic pill”. However, the study did notice a 36 percent decrease in monthly seizures in those patients who took cannabidiol. This is enough to show that there is a strong connection between the two and a potential treatment for those who really need it.

The study helps to confirm what many already believe: that cannabinoids could be used to alleviate the symptoms of epilepsy or even treat the condition entirely. This is particularly impressive considering that the patients were resistant to all other treatments in the past. Hopefully, more studies like this will be conducted in the future and a more reliable treatment can be manufactured for these patients.

More To Come.

With these studies revealing such positive results, it is very likely that we will see more studies in the future. And perhaps one day patients who suffer from conditions that seem impossible to treat, such as schizophrenia, epilepsy, and rheumatoid arthritis, will be able to achieve serious relief.